Celgene’s Revlimid Approved For Third-Line Use In Mantle Cell Lymphoma

Lenalidomide becomes first oral therapy approved in this disease but soon could be joined by ibrutinib, Pharmacyclics/J&J’s investigational agent that has received FDA “breakthrough therapy” designation.